akinohanayuki ブログ

学位を持っても、センスのない、感染制御専門薬剤師のブログ.  I have Ph.D. but less sense ID pharmacist.

Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial.

Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial.

www.ncbi.nlm.nih.gov

2016年CIDに報告された、ベトナム2施設によるデング熱に対するRCT。

スタチンとプラセボの比較。スタチンの抗炎症作用を期待する根強い声ありますね。

 

 

 

P : Vietnamese adults with a positive dengue NS1 rapid test presenting within 72 hours of fever onset.

E :  lovastatin 80mg, 5days  n= 149

C :  placebo n= 151

O : 

The primary outcome

Adverse events occurred with similar frequency in both groups (97/151 [64%] placebo vs 82/149 [55%] lovastatin; P = .13). 

The secondary outcome measures :  no difference (see, Table3)

 

T : double-blind, RCT

 

f:id:akinohanayuki:20170510060032p:plain

f:id:akinohanayuki:20170510060051p:plain

f:id:akinohanayuki:20170510060056p:plain

f:id:akinohanayuki:20170510060106p:plain

f:id:akinohanayuki:20170510060120p:plain

f:id:akinohanayuki:20170510060127p:plain

f:id:akinohanayuki:20170510060137p:plain

Viremia levels in lovastatin- and placebo-treated patients. Viremia is shown by serotype (A) and immune status (B). Values below the detection limit were imputed by half of the serotype-specific detection limits. The colored lines in each graph correspond to loess scatterplot smoothers derived from local polynomial regression fitting to data from each treatment arm. The gray background lines represent individual patient data. Overall, viremia kinetics did not differ significantly between the treatment groups. Abbreviation: DENV, dengue virus.

 

感想

デング熱にスタチンは効果なさそう。

主アウトカムを、安全性にしていることは、いただけない。

デング熱に対するレスポンスまたは、合併症出現率にするべきだと思う。

 

過去記事

 

akinohanayuki.hatenablog.com

akinohanayuki.hatenablog.com

akinohanayuki.hatenablog.com